Information  X 
Enter a valid email address

Seed Innovations Ltd (SEED)

  Print   

Friday 01 July, 2022

Seed Innovations Ltd

Investee Company Update: Little Green Pharma Ltd

RNS Number : 1052R
Seed Innovations Limited
01 July 2022
 

Feed Innovations Ltd / AIM: SEED / Sector: Closed End Investments

 

1 July 2022

 

SEED Innovations Limited

("SEED" or the "Company")

Investee Company Update: Little Green Pharma Ltd

SEED Innovations Ltd, the AIM-quoted company investing in fast-growing and industry-leading businesses with a focus on the medical cannabis, health and wellness space, notes an announcement released on the ASX by its portfolio company, Little Green Pharma Ltd ('LGP') of its annual report for the nine-month period ended 31 March 2022 (requiring a shortened annual report following a change of year end to 31 March), including key highlights for the period. 

SEED owns a holding of 7,324,796 ordinary shares in LGP representing 3.1% of LGP's issued share capital.

Alfredo Pascual, VP of Investment Analysis at SEED, commented:

"It has been an exceptional year for LGP, as it continued its growth in Australia and advanced its strategy to expand into other markets. During the period, LGP became a leading cannabis company in the European Union with its GMP-licensed Danish facility and its continued development of its supply channels into new markets such as Italy and Denmark.  

"LGP also reported strong growth with revenue of AUD10.52 million for the 9-month reporting period, an increase of 50% on the previous 12-month financial year, a significant achievement and we look forward to following LGP's progress in the next year."

Highlights

· 50% revenue growth from the previous 12-month financial year

· 63% and 64% increase in Australian patients and active prescribers respectively*

· 114% increase in international sales*

* Comparisons with the comparative reporting period of 1 July 2020 - 31 March 2021

The announcement can be viewed in full including the relevant appendices on LGP's website via the following link: https://investor.littlegreenpharma.com/site/PDF/1a906fbf-c947-4f74-8d10-7669c6af6ee4/AnnualReporttoshareholders

 

- Ends -

For further information on the Company please visit:  www.seedinnovations.com  or contact:

 

Ed McDermott 

Lance de Jersey 

SEED Innovations Ltd 

E: [email protected]

James Biddle 

Roland Cornish 

Beaumont Cornish Limited, 

Nomad 

T: (0)20 7628 3396 

Isabella Pierre 

Damon Heath 

Shard Capital Partners LLP 

Broker 

T: (0)20 7186 9927 

Catherine Leftley 

Isabelle Morris 

St Brides Partners Ltd, 

Financial PR 

E: [email protected] 

 

 

Notes 

Seed Innovations Ltd

SEED Innovations is an AIM quoted investment company focused primarily on disruptive high growth life sciences and technology businesses particularly within the medical cannabis arena. The Company's strategy is to identify early-stage opportunities that have an upcoming investment catalyst and grow its portfolio in terms of value whilst limiting the number of investee companies to a level where relevant time can be devoted to each.

 About Little Green Pharma

Little Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution. The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, being a 21,500m2 cultivation and 4,000m2 GMP manufacturing facility capable of producing over 20 tonnes of medicinal cannabis biomass per annum located in Denmark (EU) and an indoor cultivation and manufacturing facility located in Western Australia capable of producing ~3 tonnes of medicinal cannabis biomass per annum. Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets. The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems. For more information about Little Green Pharma go to: www.littlegreenpharma.com

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCUPUGPMUPPGQG

a d v e r t i s e m e n t